On November 9, 2017 Inovio Pharmaceuticals, Inc. (NASDAQ:INO) reported that the Company will participate in the following upcoming investment conferences (Press release, Inovio, NOV 9, 2017, View Source [SID1234521873]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel 2017 Healthcare Conference
Presentation and 1×1 meetings
Dr. Niranjan Y. Sardesai, COO
11:45 AM ET, November 15, 2017
New York, NY

29th Annual Piper Jaffray Healthcare Conference
Presentation and 1×1 meetings
Dr. J. Joseph Kim, President & CEO
9:00 AM ET, November 29, 2017
New York, NY

Citi’s 2017 Global Healthcare Conference
1×1 meetings only
Dr. J. Joseph Kim, President & CEO
December 6-7, 2017
New York, NY

The live and archived version of the Piper Jaffray presentation will be available on Inovio’s website at View Source

On November 9, 2017 Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, reported that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Jefferies 2017 London Healthcare Conference on November 16, 2017, at 1:20 p.m. local time (5:20 a.m. Pacific time) in London, UK (Press release, Ignyta, NOV 9, 2017, View Source [SID1234521871]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available during the presentation in the Investors section of the company’s website at View Source, and will be archived and available at that site for 14 days.

On November 9, 2017 GlycoMimetics, Inc. (Nasdaq:GLYC) reported that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows (Press release, GlycoMimetics, NOV 9, 2017, View Source [SID1234521869]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

STIFEL 2017 HEALTHCARE CONFERENCE
When: November 14, 2017 at 8:00 a.m. ET
Where: New York, NY, USA
JEFFERIES 2017 LONDON HEALTHCARE CONFERENCE
When: November 16, 2017 at 3:20 p.m. GMT
Where: London, UK

To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at www.glycomimetics.com.

On November 9, 2017 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) reported that its management will be presenting at the Jefferies 2017 London Healthcare Conference in London, UK, at the German Equity Forum in Frankfurt, Germany, and at the Annual Berenberg European Conference in Surrey, UK, and will be attending DZ BANK Equity Conference in Frankfurt, Germany, and dbAccess Pharmaceutical and Healthcare Corporate Day in London, UK (Press release, Evotec, NOV 9, 2017, View Source [SID1234521864]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2017 London Healthcare Conference, London, UK
Date: Thursday, 16 November 2017, 11.20 am GMT (12.20 pm CET, 06.20 am EST)
Webcast: Click here for the webcast
Venue: London, UK
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

DZ BANK Equity Conference, Frankfurt, Germany
Date: Wednesday, 22 November 2017
Venue: Frankfurt, Germany
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

German Equity Forum, Frankfurt, Germany
Date: Monday, 27 November 2017, 11.30 am CET (10.30 am GMT, 05.30 am EST)
Venue: Frankfurt, Germany
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

dbAccess Pharmaceutical and Healthcare Corporate Day, London, UK
Date: Thursday, 30 November 2017
Venue: London, UK
Attendee: Enno Spillner, Chief Financial Officer of Evotec AG

Annual Berenberg European Conference, Surrey, UK
Date: Wednesday, 06 December 2017, 09.45 am GMT (10.45 am CET, 04.45 am EST)
Venue: Surrey, UK
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

On November 9, 2017 Pfenex Inc. (NYSE AMERICAN: PFNX), reported that it will be presenting at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15th at 12:40 pm GMT / 7:40 pm ET (Press release, Pfenex, NOV 9, 2017, View Source2017-11-09-Pfenex-Inc-to-Present-at-the-Jefferies-2017-London-Healthcare-Conference" target="_blank" title="View Source2017-11-09-Pfenex-Inc-to-Present-at-the-Jefferies-2017-London-Healthcare-Conference" rel="nofollow">View Source [SID1234521896]). The presentation will be webcast and available for replay in the Investors Section of Pfenex’s website at www.pfenex.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (View Source), our investor relations website (View Source), press releases, SEC filings, public conference calls, corporate Twitter account (View Source), Facebook page (View Source), and LinkedIn page (View Source) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.